厄贝沙坦对老年代谢综合征患者糖脂代谢的影响研究

Influence of irbesartan on glycometabolism and lipid metabolism in gerontal patient with meta-bolic syndrome

目的:探讨厄贝沙坦对老年代谢综合征(MS)患者糖及脂类代谢的影响。方法:选择172例老年MS患者,随机分为对照组及治疗组,患者均给予生活调节、饮食控制治疗,治疗组另给予厄贝沙坦治疗,比较两组患者治疗前后血压、空腹血糖(FBG)、餐后血糖(PBG)、胰岛素抵抗指数(HOMA-IR)、胰岛素敏感指数(ISI)和体重指数(BMI)变化。分析两组患者治疗前后静脉血胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、瘦素(LEP)及脂联素(APN)水平变化。结果:治疗后治疗组SBP、DBP、FBG、PBG、HOMA-IR低于对照组,TC、LDL-C水平低于对照组,差异有统计学意义(P<0.05)。治疗后治疗组ISI、HDL-C、LEP及APN水平高于对照组,差异有统计学意义(P<0.05)。结论:厄贝沙坦能够改善MS患者胰岛素抵抗及脂类代谢异常,改善患者的临床治疗效果。

Objective： To investigate the influence of irbesartan on glycometabolism and lipid me- tabolism in gerontal patient with meta--bolic syndrome （MS）. Methods. A total of 172 gerontal patient with MS were selected and randomly divided into treatment group and control groups, all patients were given ordered to control alimentary and life style, while patients in treatment group also taken irbesartan. Changes in blood pressure, fasting blood glucose （FBG）,p ostprandial blood sugar （PBG）, insulin resist- ance index （HOMA-IR）, insulin sensitivity index（ISI） and body mass index （BMI） were compared and levels of total cholesterol （TG） high density lipoprotein cholesterol （HDL-C）, low density lipoprotein （LDL-C）, leptin （LEP） and adiponectin （APN） were analyzed and compared between the two groups. Re- suits： After treatment, levels of SBP, DBP, FBG, PBG, HOMA-IR, TC, LDC-C of the treatment group were all significant lower than that of the control group （P^0.05） ~ but ISI, HDL-C, LEP and APN lev- els were all higher （P^0.05）. Oonclusions： Irbesartan can improve insulin resistance index and lipid dys- metabolism and improve clinal therapeutic efficacy in patients with meta-bolic syndrome.